Latest Pharma Insights
Daiichi Sankyo’s Oncology Strategy: 5 Years, 5 Drugs, Top 5 Cancer Companies
The Japanese drugmaker is especially leaning on its growing portfolio of antibody-drug conjugates with deruxtecan payloads as it builds out its oncology business.
Scrip - May 11, 2026
The Japanese drugmaker is especially leaning on its growing portfolio of antibody-drug conjugates with deruxtecan payloads as it builds out its oncology business.
Scrip - May 11, 2026
Novo Nordisk Hands Parkinson’s Cell Therapy To Cellular Intelligence
Deal Snapshot: Since ending cell therapy efforts last September to focus on diabetes and obesity, Novo has been offloading cell therapy assets to Heartseed, Aspect and now Cellular Intelligence.
Scrip - May 11, 2026
Deal Snapshot: Since ending cell therapy efforts last September to focus on diabetes and obesity, Novo has been offloading cell therapy assets to Heartseed, Aspect and now Cellular Intelligence.
Scrip - May 11, 2026
Liquidia And United Duke It Out In Treprostinil Market
Liquidia’s Yutrepia generated $129.9m in the first quarter as a new competitor to United Therapeutics’ similar product, Tyvaso, but United has its sights set on ralinepag.
Scrip - May 11, 2026
Liquidia’s Yutrepia generated $129.9m in the first quarter as a new competitor to United Therapeutics’ similar product, Tyvaso, but United has its sights set on ralinepag.
Scrip - May 11, 2026
Almirall Hails Ebglyss Growth And Pipeline Advances
The Barcelona-based group also trumpeted another China dermatology deal, this time with Huaota.
Scrip - May 11, 2026
The Barcelona-based group also trumpeted another China dermatology deal, this time with Huaota.
Scrip - May 11, 2026
How People Talk To AI About Health Revealed By Microsoft Study
Research from Microsoft analyzes Copilot conversations to understand what kinds of health questions users ask AI and how this could affect response design.
HBW Insight - May 11, 2026
Research from Microsoft analyzes Copilot conversations to understand what kinds of health questions users ask AI and how this could affect response design.
HBW Insight - May 11, 2026
Digestive Category Is ‘Strong Anchor’ For Opella In First Year Of Independence
Exclusive: Opella speaks to HBW Insight about its financial performance in 2025 and gives an insight into some of its priorities for this year.
HBW Insight - May 11, 2026
Exclusive: Opella speaks to HBW Insight about its financial performance in 2025 and gives an insight into some of its priorities for this year.
HBW Insight - May 11, 2026
Mobia Medical Goes Public, Banking On Sole FDA-Approved Stroke Implant
Mobia Medical began trading on Nasdaq Friday after pricing its IPO at $15 per share, becoming only the second medtech company to go public in 2026. It plans to deploy the bulk of the proceeds toward commercial expansion of Vivistim.
Medtech Insight - May 11, 2026
Mobia Medical began trading on Nasdaq Friday after pricing its IPO at $15 per share, becoming only the second medtech company to go public in 2026. It plans to deploy the bulk of the proceeds toward commercial expansion of Vivistim.
Medtech Insight - May 11, 2026
Pipeline Watch: Six Approvals And Three Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - May 11, 2026
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - May 11, 2026
Fifth Veeva MedTech Summit Focuses On Practical AI Adoption, Operational Change
Veeva's fifth MedTech Summit draws more than 400 executives to discuss key issues from AI operationalization, QMSR compliance and digital transformation. Medtech Insight spoke with Veeva MedTech president Seth Goldenberg about what to expect at the event, including key sessions and focus areas.
Medtech Insight - May 11, 2026
Veeva's fifth MedTech Summit draws more than 400 executives to discuss key issues from AI operationalization, QMSR compliance and digital transformation. Medtech Insight spoke with Veeva MedTech president Seth Goldenberg about what to expect at the event, including key sessions and focus areas.
Medtech Insight - May 11, 2026
Alvotech Assured After FDA Facility Feedback
Alvotech has sounded a note of optimism over its pending US biosimilar filings, after an FDA inspection of its Reykjavik facility did not raise “substantial issues”. Meanwhile, the firm has just announced a US manufacturing deal with Fujifilm that delivers on its dual-source manufacturing plans.
Generics Bulletin - May 11, 2026
Alvotech has sounded a note of optimism over its pending US biosimilar filings, after an FDA inspection of its Reykjavik facility did not raise “substantial issues”. Meanwhile, the firm has just announced a US manufacturing deal with Fujifilm that delivers on its dual-source manufacturing plans.
Generics Bulletin - May 11, 2026
Novo’s MicroRNA Therapy Disappoints In Post-Heart Attack Patients
The novel treatment acquired with Cardior failed to improve heart function in a Phase II study in hard-to-treat patients, but further trials are ongoing.
Scrip - May 11, 2026
The novel treatment acquired with Cardior failed to improve heart function in a Phase II study in hard-to-treat patients, but further trials are ongoing.
Scrip - May 11, 2026
AI Becomes ‘The Equalizer’ In Healthcare Delivery
Healthcare is beginning to benefit from the impact of AI, “but it’s just a small percentage of what we expect to see long term,” Avner Halperin, CEO of Sheba Medical Center’s commercialization arm, told In Vivo on the eve of Biomed Israel 2026.
In Vivo - May 11, 2026
Healthcare is beginning to benefit from the impact of AI, “but it’s just a small percentage of what we expect to see long term,” Avner Halperin, CEO of Sheba Medical Center’s commercialization arm, told In Vivo on the eve of Biomed Israel 2026.
In Vivo - May 11, 2026
Biosimilar Streamlining Means All Should ‘Reach The Fruits’
Regulators say comparative efficacy studies will no longer be routine for many biosimilars, but the next phase will test how far the tailored approach can go, and whether markets can keep pace, as discussed at Medicines for Europe’s recent Biosimilar Medicines Conference.
Generics Bulletin - May 11, 2026
Regulators say comparative efficacy studies will no longer be routine for many biosimilars, but the next phase will test how far the tailored approach can go, and whether markets can keep pace, as discussed at Medicines for Europe’s recent Biosimilar Medicines Conference.
Generics Bulletin - May 11, 2026
Towa Writes Down Sunsho With $94m Impairment
Ahead of reporting full-year results later this week, Japan’s Towa has announced a significant write-down of almost $100m in the value of its Sunsho business.
Generics Bulletin - May 11, 2026
Ahead of reporting full-year results later this week, Japan’s Towa has announced a significant write-down of almost $100m in the value of its Sunsho business.
Generics Bulletin - May 11, 2026
MHRA Outlines Plans For CE Mark Recognition, Early Access Pathway
At RAPS 2026, the MHRA announced updates on its consultation for indefinite CE Mark recognition and its own version of breakthrough device designation.
Medtech Insight - May 11, 2026
At RAPS 2026, the MHRA announced updates on its consultation for indefinite CE Mark recognition and its own version of breakthrough device designation.
Medtech Insight - May 11, 2026
Over The Counter: How Agentic AI Could Reshape Consumer Health, With IQVIA’s Volker Spitzer
In the latest Over the Counter podcast, IQVIA’s Volker Spitzer discusses how emerging “agentic AI” could reshape consumer health by acting as a persistent, autonomous advisor, raising questions around trust, regulation, and the future role of pharmacists.
HBW Insight - May 11, 2026
In the latest Over the Counter podcast, IQVIA’s Volker Spitzer discusses how emerging “agentic AI” could reshape consumer health by acting as a persistent, autonomous advisor, raising questions around trust, regulation, and the future role of pharmacists.
HBW Insight - May 11, 2026
Innovative Trial Designs And RMAT Pathways: Accelerating Rare Disease Approvals In 2026
Rare disease drug development is accelerating via RMAT pathways, adaptive trials, and RWE – but faster approvals must translate into sustained patient access.
In Vivo - May 11, 2026
Rare disease drug development is accelerating via RMAT pathways, adaptive trials, and RWE – but faster approvals must translate into sustained patient access.
In Vivo - May 11, 2026
Paul Stoffels’s Playbook For Impactful Innovation, How India Can Step Up
Industry doyen and J&J research veteran Paul Stoffels talks about the core principles behind getting innovation right and developing the best science with highest impact on disease, sharing experiences from his storied career along the way.
In Vivo - May 11, 2026
Industry doyen and J&J research veteran Paul Stoffels talks about the core principles behind getting innovation right and developing the best science with highest impact on disease, sharing experiences from his storied career along the way.
In Vivo - May 11, 2026
Korea Q1 Roundup: Hanmi Gears For Obesity Launch, Strong Growth For SK Biopharm
Major South Korean pharma firms’ mostly solid first-quarter earnings, helped by overseas sales of in-house prescription drugs.
Scrip - May 11, 2026
Major South Korean pharma firms’ mostly solid first-quarter earnings, helped by overseas sales of in-house prescription drugs.
Scrip - May 11, 2026
Curacle Inks $1bn Bispecific Deal With Memento
Curacle and MabTics out-license MT-103, a bispecific antibody targeting retinal diseases, to US-based Memento Medicines in a deal potentially worth just over $1bn.
Scrip - May 11, 2026
Curacle and MabTics out-license MT-103, a bispecific antibody targeting retinal diseases, to US-based Memento Medicines in a deal potentially worth just over $1bn.
Scrip - May 11, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Novo winning early oral obesity market; GSK deal bolsters downstream obesity strategy; brighter Pfizer outlook due to Vyndamax settlements; China dominates record novel drug launches; and J&J drops two lymphoma CAR-Ts.
Scrip - May 11, 2026
In this week's episode: Novo winning early oral obesity market; GSK deal bolsters downstream obesity strategy; brighter Pfizer outlook due to Vyndamax settlements; China dominates record novel drug launches; and J&J drops two lymphoma CAR-Ts.
Scrip - May 11, 2026
US FDA Piloting AI-Enabled One-Day Inspections To Expand Oversight, Improve Efficiency
One-day inspections could help broaden the FDA's domestic and foreign surveillance reach and would employ artificial intelligence to identify low-risk facilities.
HBW Insight - May 11, 2026
One-day inspections could help broaden the FDA's domestic and foreign surveillance reach and would employ artificial intelligence to identify low-risk facilities.
HBW Insight - May 11, 2026
Growing GRAS Change From Idea To Proposed Rule Takes Time – FDA Foods Program Chief
“Any reports that the administration doesn't support” HHS Secretary Kennedy’s proposal to cut the GRAS self-affirmation option, “I would say are not accurate,” says FDA Human Foods Program director Kyle Diamantas.
HBW Insight - May 11, 2026
“Any reports that the administration doesn't support” HHS Secretary Kennedy’s proposal to cut the GRAS self-affirmation option, “I would say are not accurate,” says FDA Human Foods Program director Kyle Diamantas.
HBW Insight - May 11, 2026
‘Dietary Substance For Use To Supplement The Diet’? US FDA Plans To Answer With Guidance
“Getting some clarity so we all know what we're looking at when we think about a dietary substance for use by man to supplement the diet by increasing the total dietary intake. It's clear as mud,” says FDA supplement programs director Cara Welch.
HBW Insight - May 11, 2026
“Getting some clarity so we all know what we're looking at when we think about a dietary substance for use by man to supplement the diet by increasing the total dietary intake. It's clear as mud,” says FDA supplement programs director Cara Welch.
HBW Insight - May 11, 2026
Daiichi Sankyo’s Oncology Strategy: 5 Years, 5 Drugs, Top 5 Cancer Companies
The Japanese drugmaker is especially leaning on its growing portfolio of antibody-drug conjugates with deruxtecan payloads as it builds out its oncology business.
Scrip - May 11, 2026
The Japanese drugmaker is especially leaning on its growing portfolio of antibody-drug conjugates with deruxtecan payloads as it builds out its oncology business.
Scrip - May 11, 2026
Novo Nordisk Hands Parkinson’s Cell Therapy To Cellular Intelligence
Deal Snapshot: Since ending cell therapy efforts last September to focus on diabetes and obesity, Novo has been offloading cell therapy assets to Heartseed, Aspect and now Cellular Intelligence.
Scrip - May 11, 2026
Deal Snapshot: Since ending cell therapy efforts last September to focus on diabetes and obesity, Novo has been offloading cell therapy assets to Heartseed, Aspect and now Cellular Intelligence.
Scrip - May 11, 2026
Liquidia And United Duke It Out In Treprostinil Market
Liquidia’s Yutrepia generated $129.9m in the first quarter as a new competitor to United Therapeutics’ similar product, Tyvaso, but United has its sights set on ralinepag.
Scrip - May 11, 2026
Liquidia’s Yutrepia generated $129.9m in the first quarter as a new competitor to United Therapeutics’ similar product, Tyvaso, but United has its sights set on ralinepag.
Scrip - May 11, 2026
Almirall Hails Ebglyss Growth And Pipeline Advances
The Barcelona-based group also trumpeted another China dermatology deal, this time with Huaota.
Scrip - May 11, 2026
The Barcelona-based group also trumpeted another China dermatology deal, this time with Huaota.
Scrip - May 11, 2026
Pipeline Watch: Six Approvals And Three Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - May 11, 2026
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - May 11, 2026
Novo’s MicroRNA Therapy Disappoints In Post-Heart Attack Patients
The novel treatment acquired with Cardior failed to improve heart function in a Phase II study in hard-to-treat patients, but further trials are ongoing.
Scrip - May 11, 2026
The novel treatment acquired with Cardior failed to improve heart function in a Phase II study in hard-to-treat patients, but further trials are ongoing.
Scrip - May 11, 2026
Korea Q1 Roundup: Hanmi Gears For Obesity Launch, Strong Growth For SK Biopharm
Major South Korean pharma firms’ mostly solid first-quarter earnings, helped by overseas sales of in-house prescription drugs.
Scrip - May 11, 2026
Major South Korean pharma firms’ mostly solid first-quarter earnings, helped by overseas sales of in-house prescription drugs.
Scrip - May 11, 2026
Curacle Inks $1bn Bispecific Deal With Memento
Curacle and MabTics out-license MT-103, a bispecific antibody targeting retinal diseases, to US-based Memento Medicines in a deal potentially worth just over $1bn.
Scrip - May 11, 2026
Curacle and MabTics out-license MT-103, a bispecific antibody targeting retinal diseases, to US-based Memento Medicines in a deal potentially worth just over $1bn.
Scrip - May 11, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Novo winning early oral obesity market; GSK deal bolsters downstream obesity strategy; brighter Pfizer outlook due to Vyndamax settlements; China dominates record novel drug launches; and J&J drops two lymphoma CAR-Ts.
Scrip - May 11, 2026
In this week's episode: Novo winning early oral obesity market; GSK deal bolsters downstream obesity strategy; brighter Pfizer outlook due to Vyndamax settlements; China dominates record novel drug launches; and J&J drops two lymphoma CAR-Ts.
Scrip - May 11, 2026
Mobia Medical Goes Public, Banking On Sole FDA-Approved Stroke Implant
Mobia Medical began trading on Nasdaq Friday after pricing its IPO at $15 per share, becoming only the second medtech company to go public in 2026. It plans to deploy the bulk of the proceeds toward commercial expansion of Vivistim.
Medtech Insight - May 11, 2026
Mobia Medical began trading on Nasdaq Friday after pricing its IPO at $15 per share, becoming only the second medtech company to go public in 2026. It plans to deploy the bulk of the proceeds toward commercial expansion of Vivistim.
Medtech Insight - May 11, 2026
Fifth Veeva MedTech Summit Focuses On Practical AI Adoption, Operational Change
Veeva's fifth MedTech Summit draws more than 400 executives to discuss key issues from AI operationalization, QMSR compliance and digital transformation. Medtech Insight spoke with Veeva MedTech president Seth Goldenberg about what to expect at the event, including key sessions and focus areas.
Medtech Insight - May 11, 2026
Veeva's fifth MedTech Summit draws more than 400 executives to discuss key issues from AI operationalization, QMSR compliance and digital transformation. Medtech Insight spoke with Veeva MedTech president Seth Goldenberg about what to expect at the event, including key sessions and focus areas.
Medtech Insight - May 11, 2026
MHRA Outlines Plans For CE Mark Recognition, Early Access Pathway
At RAPS 2026, the MHRA announced updates on its consultation for indefinite CE Mark recognition and its own version of breakthrough device designation.
Medtech Insight - May 11, 2026
At RAPS 2026, the MHRA announced updates on its consultation for indefinite CE Mark recognition and its own version of breakthrough device designation.
Medtech Insight - May 11, 2026
How People Talk To AI About Health Revealed By Microsoft Study
Research from Microsoft analyzes Copilot conversations to understand what kinds of health questions users ask AI and how this could affect response design.
HBW Insight - May 11, 2026
Research from Microsoft analyzes Copilot conversations to understand what kinds of health questions users ask AI and how this could affect response design.
HBW Insight - May 11, 2026
Digestive Category Is ‘Strong Anchor’ For Opella In First Year Of Independence
Exclusive: Opella speaks to HBW Insight about its financial performance in 2025 and gives an insight into some of its priorities for this year.
HBW Insight - May 11, 2026
Exclusive: Opella speaks to HBW Insight about its financial performance in 2025 and gives an insight into some of its priorities for this year.
HBW Insight - May 11, 2026
Over The Counter: How Agentic AI Could Reshape Consumer Health, With IQVIA’s Volker Spitzer
In the latest Over the Counter podcast, IQVIA’s Volker Spitzer discusses how emerging “agentic AI” could reshape consumer health by acting as a persistent, autonomous advisor, raising questions around trust, regulation, and the future role of pharmacists.
HBW Insight - May 11, 2026
In the latest Over the Counter podcast, IQVIA’s Volker Spitzer discusses how emerging “agentic AI” could reshape consumer health by acting as a persistent, autonomous advisor, raising questions around trust, regulation, and the future role of pharmacists.
HBW Insight - May 11, 2026
US FDA Piloting AI-Enabled One-Day Inspections To Expand Oversight, Improve Efficiency
One-day inspections could help broaden the FDA's domestic and foreign surveillance reach and would employ artificial intelligence to identify low-risk facilities.
HBW Insight - May 11, 2026
One-day inspections could help broaden the FDA's domestic and foreign surveillance reach and would employ artificial intelligence to identify low-risk facilities.
HBW Insight - May 11, 2026
Growing GRAS Change From Idea To Proposed Rule Takes Time – FDA Foods Program Chief
“Any reports that the administration doesn't support” HHS Secretary Kennedy’s proposal to cut the GRAS self-affirmation option, “I would say are not accurate,” says FDA Human Foods Program director Kyle Diamantas.
HBW Insight - May 11, 2026
“Any reports that the administration doesn't support” HHS Secretary Kennedy’s proposal to cut the GRAS self-affirmation option, “I would say are not accurate,” says FDA Human Foods Program director Kyle Diamantas.
HBW Insight - May 11, 2026
‘Dietary Substance For Use To Supplement The Diet’? US FDA Plans To Answer With Guidance
“Getting some clarity so we all know what we're looking at when we think about a dietary substance for use by man to supplement the diet by increasing the total dietary intake. It's clear as mud,” says FDA supplement programs director Cara Welch.
HBW Insight - May 11, 2026
“Getting some clarity so we all know what we're looking at when we think about a dietary substance for use by man to supplement the diet by increasing the total dietary intake. It's clear as mud,” says FDA supplement programs director Cara Welch.
HBW Insight - May 11, 2026
Alvotech Assured After FDA Facility Feedback
Alvotech has sounded a note of optimism over its pending US biosimilar filings, after an FDA inspection of its Reykjavik facility did not raise “substantial issues”. Meanwhile, the firm has just announced a US manufacturing deal with Fujifilm that delivers on its dual-source manufacturing plans.
Generics Bulletin - May 11, 2026
Alvotech has sounded a note of optimism over its pending US biosimilar filings, after an FDA inspection of its Reykjavik facility did not raise “substantial issues”. Meanwhile, the firm has just announced a US manufacturing deal with Fujifilm that delivers on its dual-source manufacturing plans.
Generics Bulletin - May 11, 2026
Biosimilar Streamlining Means All Should ‘Reach The Fruits’
Regulators say comparative efficacy studies will no longer be routine for many biosimilars, but the next phase will test how far the tailored approach can go, and whether markets can keep pace, as discussed at Medicines for Europe’s recent Biosimilar Medicines Conference.
Generics Bulletin - May 11, 2026
Regulators say comparative efficacy studies will no longer be routine for many biosimilars, but the next phase will test how far the tailored approach can go, and whether markets can keep pace, as discussed at Medicines for Europe’s recent Biosimilar Medicines Conference.
Generics Bulletin - May 11, 2026
Towa Writes Down Sunsho With $94m Impairment
Ahead of reporting full-year results later this week, Japan’s Towa has announced a significant write-down of almost $100m in the value of its Sunsho business.
Generics Bulletin - May 11, 2026
Ahead of reporting full-year results later this week, Japan’s Towa has announced a significant write-down of almost $100m in the value of its Sunsho business.
Generics Bulletin - May 11, 2026
AI Becomes ‘The Equalizer’ In Healthcare Delivery
Healthcare is beginning to benefit from the impact of AI, “but it’s just a small percentage of what we expect to see long term,” Avner Halperin, CEO of Sheba Medical Center’s commercialization arm, told In Vivo on the eve of Biomed Israel 2026.
In Vivo - May 11, 2026
Healthcare is beginning to benefit from the impact of AI, “but it’s just a small percentage of what we expect to see long term,” Avner Halperin, CEO of Sheba Medical Center’s commercialization arm, told In Vivo on the eve of Biomed Israel 2026.
In Vivo - May 11, 2026
Innovative Trial Designs And RMAT Pathways: Accelerating Rare Disease Approvals In 2026
Rare disease drug development is accelerating via RMAT pathways, adaptive trials, and RWE – but faster approvals must translate into sustained patient access.
In Vivo - May 11, 2026
Rare disease drug development is accelerating via RMAT pathways, adaptive trials, and RWE – but faster approvals must translate into sustained patient access.
In Vivo - May 11, 2026
Paul Stoffels’s Playbook For Impactful Innovation, How India Can Step Up
Industry doyen and J&J research veteran Paul Stoffels talks about the core principles behind getting innovation right and developing the best science with highest impact on disease, sharing experiences from his storied career along the way.
In Vivo - May 11, 2026
Industry doyen and J&J research veteran Paul Stoffels talks about the core principles behind getting innovation right and developing the best science with highest impact on disease, sharing experiences from his storied career along the way.
In Vivo - May 11, 2026